Atacand (candesartan cilexetil) tablets 16 mg. №28

Atacand (candesartan cilexetil) tablets 16 mg. №28

$74.00

Manufacturer: Germany

Atacand (candesartan cilexetil) is used to treat hypertension. Keeping high blood pressure under control reduces the risk of stroke and heart attack.

Category:

Description

Ingredients

active ingredient: 1 tablet contains candesartan cilexetil 8 mg;

excipients: calcium carboxymethylcellulose; hydroxypropyl cellulose; iron oxide (E172) lactose monohydrate, magnesium stearate starch corn polyethylene glycol 8000.

Dosage form

Pills.

Basic physical and chemical properties:

8 mg: light pink, round, biconvex tablet, scored and debossed with A/CG on one side and 008 on the other side;

Pharmacotherapeutic group

Angiotensin II receptor antagonists. ATX code C09C A06.

Pharmacodynamics

Mechanism of action

Angiotensin II is the main vasoactive hormone renin-angiotensin-, which plays a role in the pathophysiological mechanisms of the development of hypertension, heart failure and other cardiovascular diseases. It also plays a role in the pathogenesis of hypertrophy and target organ damage. The main physiological effects of angiotensin II, such as vasoconstriction, stimulation of aldosterone, regulation of salt and water homeostasis, and stimulation of cell growth, occur with the participation of type 1 (AT1) receptors.

Pharmacodynamic effects

Candesartan cilexetil is a precursor drug suitable for oral administration. It is rapidly converted to the active substance, candesartan, by ether hydrolysis upon absorption in the digestive tract. Candesartan is an ARAII selective for the AT1 receptor, with strong binding and slow dissociation from the receptor. It has no agonistic activity.

Candesartan is not inhibited by ACE, which converts angiotensin I to angiotensin II and destroys bradykinin. There was no effect on ACE and potentiation of bradykinin or substance P. In controlled clinical studies comparing candesartan with ACE inhibitors, the incidence of cough was lower in patients treated with candesartan cilexetil. Candesartan does not bind or block other hormone receptors or ion channels important in the regulation of the cardiovascular system. Antagonism to angiotensin II receptors (AT1) leads to a dose-dependent increase in plasma levels of renin, angiotensin I and angiotensin II, as well as a decrease in plasma aldosterone concentration.

Indications

Treatment of essential hypertension in adults.

Treatment of adult patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction ≤ 40%) as adjunctive therapy to ACE inhibitors (ACE) or in cases of intolerance to ACE inhibitors.

Contraindications

Hypersensitivity to candesartan cilexetil or to any of the excipients.

Severe liver dysfunction and/or cholestasis.

In patients with diabetes mellitus or impaired renal function (GFR <60 ml / min / 1.73 m2), the simultaneous use of Atacand and drugs containing aliskiren is contraindicated.

Dosage and administration

Dosing for hypertension

The recommended starting dose and usual maintenance dose of Atacand is 8 mg once daily. In most cases, the antihypertensive effect is achieved within 4 weeks. In some patients with insufficient blood pressure control, the dose can be increased to 16 mg 1 time per day and up to a maximum of 32 mg 1 time per day. Therapy requires adjustment according to the blood pressure response. Atacand (candesartan cilexetil) can be used together with other antihypertensive drugs. It was noted that the addition of hydrochlorothiazide provides an additional antihypertensive effect with different doses of Atacand.

Elderly patients

Correction of the initial dose in elderly patients is not required.

Patients with a decrease in intravascular volume of circulating blood

In patients at risk of developing arterial hypotension, such as patients with possible dehydration, an initial dose of 4 mg may be considered.

Patients with impaired renal function

The initial dose in patients with impaired renal function, including patients on hemodialysis, is 4 mg. The dose should be adjusted according to the response to treatment. The experience of using the drug in patients with impaired renal function of a very severe degree or at the terminal stage (Clcreatinine <15 ml / min) is limited (see section “Peculiarities of use”).

Patients with impaired liver function

For patients with mild to moderate hepatic impairment, the recommended starting dose is 4 mg once daily. The dose may be adjusted according to the response to treatment. Patients with severe liver dysfunction and / or cholestasis Atacand is contraindicated.

Negroid Patients

In patients of the Negroid race, the antihypertensive effect of candesartan is less pronounced than in patients of other races. Thus, the need for an increase in the dose of Atacand (candesartan cilexetil) and concomitant therapy for blood pressure control may occur more often in patients of the Negroid race than in patients of other races.

Dosing in heart failure

The recommended starting dose of Atacand (candesartan cilexetil) is 4 mg once daily. An increase to the target dose of 32 mg 1 time per day (maximum dose) or a high tolerated dose occurs by doubling the dose at intervals of at least 2 weeks. Evaluation of patients with heart failure should always include an assessment of renal function, including monitoring of creatinine and serum potassium. Atacand may be used with other heart failure treatments, including ACE inhibitors, beta-blockers, diuretics, and digitalis preparations, or a combination of these drugs. Patients with symptoms of heart failure, despite optimal standard therapy for heart failure, with intolerance to mineralocorticoid receptor antagonists, Atacand can be used simultaneously with ACE inhibitors. The combination of an ACE inhibitor, potassium-sparing diuretics and Atacand is not recommended; its appointment should be considered only after a thorough assessment of the potential benefits and risks.

Special patient groups

Adjustment of the initial dose in elderly patients or patients with a decrease in intravascular volume of circulating blood, or with impaired renal function or with mild or moderate hepatic impairment is not needed.

Children

The safety and efficacy of Atacand (candesartan cilexetil) in children from birth to 18 years of age for the treatment of heart failure has not been established. No data available.

Mode of application

For oral use.

Atacand (candesartan cilexetil) should be taken once a day, regardless of food intake.

Eating does not affect the bioavailability of candesartan.

Related products